Navitoclax: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{DISPLAYTITLE:Navitoclax}} | |||
== | == Navitoclax == | ||
Navitoclax | [[File:Navitoclax.svg|thumb|right|Chemical structure of Navitoclax]] | ||
'''Navitoclax''' is a small molecule inhibitor of the [[Bcl-2 family]] of proteins, which are involved in the regulation of [[apoptosis]]. It is primarily used in the field of [[oncology]] as a potential therapeutic agent for the treatment of various types of [[cancer]]. | |||
== Mechanism of Action == | == Mechanism of Action == | ||
Navitoclax | Navitoclax functions by binding to and inhibiting the activity of certain proteins in the Bcl-2 family, including [[Bcl-2]], [[Bcl-xL]], and [[Bcl-w]]. These proteins are known to prevent the process of apoptosis, or programmed cell death, in cancer cells. By inhibiting these proteins, Navitoclax promotes apoptosis, thereby reducing the survival of cancer cells. | ||
== Clinical | == Clinical Applications == | ||
Navitoclax has been | Navitoclax has been investigated in clinical trials for its efficacy in treating several types of cancer, including [[chronic lymphocytic leukemia]] (CLL), [[small cell lung cancer]] (SCLC), and other hematological malignancies. It is often studied in combination with other chemotherapeutic agents to enhance its anti-cancer effects. | ||
== Side Effects == | == Side Effects == | ||
The use of Navitoclax can lead to several side effects, the most notable being [[thrombocytopenia]], or a reduction in platelet count, which can increase the risk of bleeding. Other side effects may include [[nausea]], [[fatigue]], and [[diarrhea]]. | |||
== Research and Development == | |||
Navitoclax is part of a broader class of drugs known as [[BH3 mimetics]], which are designed to mimic the activity of the BH3-only proteins that naturally promote apoptosis. Ongoing research is focused on improving the selectivity and efficacy of Navitoclax and similar compounds, as well as reducing their side effects. | |||
== | == Related Pages == | ||
* [[Apoptosis]] | |||
* [[Bcl-2 family]] | |||
* [[Chronic lymphocytic leukemia]] | |||
* [[Small cell lung cancer]] | |||
* [[BH3 mimetics]] | |||
[[Category: | [[Category:Anticancer drugs]] | ||
[[Category: | [[Category:Apoptosis]] | ||
Latest revision as of 03:36, 13 February 2025
[edit]
Navitoclax is a small molecule inhibitor of the Bcl-2 family of proteins, which are involved in the regulation of apoptosis. It is primarily used in the field of oncology as a potential therapeutic agent for the treatment of various types of cancer.
Mechanism of Action[edit]
Navitoclax functions by binding to and inhibiting the activity of certain proteins in the Bcl-2 family, including Bcl-2, Bcl-xL, and Bcl-w. These proteins are known to prevent the process of apoptosis, or programmed cell death, in cancer cells. By inhibiting these proteins, Navitoclax promotes apoptosis, thereby reducing the survival of cancer cells.
Clinical Applications[edit]
Navitoclax has been investigated in clinical trials for its efficacy in treating several types of cancer, including chronic lymphocytic leukemia (CLL), small cell lung cancer (SCLC), and other hematological malignancies. It is often studied in combination with other chemotherapeutic agents to enhance its anti-cancer effects.
Side Effects[edit]
The use of Navitoclax can lead to several side effects, the most notable being thrombocytopenia, or a reduction in platelet count, which can increase the risk of bleeding. Other side effects may include nausea, fatigue, and diarrhea.
Research and Development[edit]
Navitoclax is part of a broader class of drugs known as BH3 mimetics, which are designed to mimic the activity of the BH3-only proteins that naturally promote apoptosis. Ongoing research is focused on improving the selectivity and efficacy of Navitoclax and similar compounds, as well as reducing their side effects.
